S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
[Urgent!] Generational Wealth Gameplan (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
1970’s computer coder issues shocking A.I. warning (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
The only accurate crypto trading system I know … (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
[Urgent!] Generational Wealth Gameplan (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
1970’s computer coder issues shocking A.I. warning (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
The only accurate crypto trading system I know … (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
[Urgent!] Generational Wealth Gameplan (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
1970’s computer coder issues shocking A.I. warning (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
The only accurate crypto trading system I know … (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
S&P 500   5,011.12
DOW   37,775.38
QQQ   423.41
What's Driving Tesla Lower Ahead of its Earnings?
[Urgent!] Generational Wealth Gameplan (Ad)
Stock market today: Wall Street drifts to a mixed finish as yields tick higher
How major US stock indexes fared Thursday, 4/18/2024
1970’s computer coder issues shocking A.I. warning (Ad)
3 Steel Stocks Could Soar on New China Tariffs
These are the Top 4 Stocks for Buybacks in 2024
The only accurate crypto trading system I know … (Ad)
CSX Co.: The Railroad Powering Ahead with an Earnings Beat
'There is no time to waste': EU leaders want to boost competitiveness to close gap with US and China
Free Trial
ASX:ACW

Actinogen Medical (ACW) Stock Price, News & Analysis

→ The “Perfect Storm” for Gold (From Gold Safe Exchange) (Ad)
Free ACW Stock Alerts
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
275,000 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
8.76%
Price Target
N/A
Stock Analysis
Stock Analysis

About Actinogen Medical

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer's disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

ACW Stock News Headlines

April 16, 2024 | msn.com
Actinogen treats first subject in Alzheimer’s disease therapy trial
April 15, 2024 | finanznachrichten.de
Actinogen Medical Limited: First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
April 15, 2024 | finance.yahoo.com
First patient treated in Actinogen's XanaMIA phase 2b Alzheimer's disease trial
March 12, 2024 | finance.yahoo.com
Investors in Actinogen Medical (ASX:ACW) have unfortunately lost 53% over the last year
February 28, 2024 | proactiveinvestors.com.au
Actinogen Medical delivers strong half-year results as it develops novel therapy
February 27, 2024 | au.investing.com
Actinogen Medical on track to deliver two key Phase 2 trial results in next 18 months
February 22, 2024 | msn.com
Diagnosing mental disorder through sleep: How TrivarX could capture this huge research market
April 18, 2024 | DTI (Ad)
Biden’s $374B Giveaway Into This Sector
Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here
January 30, 2024 | finance.yahoo.com
Will Actinogen Medical (ASX:ACW) Spend Its Cash Wisely?
January 24, 2024 | finance.yahoo.com
Positive Xanamem® human PET study published in the Journal of Alzheimer's Disease demonstrating robust CNS[1] target enzyme occupancy
December 13, 2023 | morningstar.com
Actinogen Medical Ltd ACW
November 28, 2023 | finance.yahoo.com
Actinogen XanaCIDD Phase 2a trial in patients with depression and cognitive impairment: enrolment accelerating and on track for results in second quarter of 2024
November 10, 2023 | finance.yahoo.com
Shareholders May Be A Bit More Conservative With Actinogen Medical Limited's (ASX:ACW) CEO Compensation For Now
October 13, 2023 | finance.yahoo.com
Actinogen to present progress on Phase 2 trials at the BIO Investor Forum, San Francisco and Clinical Trials on Alzheimer's Disease (CTAD) Conference, Boston
September 26, 2023 | finance.yahoo.com
Actinogen optimizes XanaMIA Phase 2b Alzheimer's disease trial design and provides general business update
May 31, 2023 | finance.yahoo.com
Actinogen to present progress on Cognitive Impairment in Depression and Alzheimer's Disease Phase 2 trials at the BIO International Convention
May 24, 2023 | travel.usnews.com
The 5 Best Travel Medical Insurance Plans for 2023
April 3, 2023 | uk.finance.yahoo.com
Investors in Actinogen Medical (ASX:ACW) have made a strong return of 215% over the past three years
March 30, 2023 | finance.yahoo.com
Actinogen presents positive Phase 2a Xanamem data in at ADPD™ Alzheimer's and Parkinson's diseases conference
March 27, 2023 | finance.yahoo.com
Actinogen Medical Limited (ATGGF)
January 12, 2023 | finance.yahoo.com
Here's Why We're Not Too Worried About Actinogen Medical's (ASX:ACW) Cash Burn Situation
December 22, 2022 | finance.yahoo.com
FDA agrees to Actinogen six-month Phase 2b Alzheimer's Disease trial
December 14, 2022 | finance.yahoo.com
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial
December 1, 2022 | reuters.com
Actinogen Medical Ltd
October 25, 2022 | uk.finance.yahoo.com
Investors in Actinogen Medical (ASX:ACW) have made a splendid return of 212% over the past three years
October 11, 2022 | benzinga.com
Actinogen Medical Stock (OTC:ATGGF), Earnings Estimates, EPS, and Revenue
See More Headlines
Receive ACW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Actinogen Medical and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
ASX:ACW
CUSIP
N/A
CIK
N/A
Web
www.actinogen.com.au
Phone
61 2 8964 7401
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
A($0.01)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-14,870,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-106.02%
Return on Assets
-59.24%

Debt

Debt-to-Equity Ratio
0.37
Current Ratio
5.42
Quick Ratio
13.73

Sales & Book Value

Annual Sales
$4.79 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
2.38
Book Value
N/A
Price / Book
N/A

Miscellaneous

Outstanding Shares
2,330,000,000
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable
Beta
2.28
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Steven G. Gourlay ) (Age 64)
    FRACP, M.B.A., MBBS (M.D., Ph.D., MD, CEO & Director
    Comp: $514.44k
  • Dr. Dana C. Hilt M.D. (Age 71)
    Chief Medical Officer & Member of Depression and Cognition Clinical Advisory Board
    Comp: $385.4k
  • Prof. Paul Rolan D.C.P.S.A.
    F.F.P.M., F.R.A.C.P., M.B.B.S., M.D., Head of Clinical Pharmacology & Lead Physician and Depression
  • Mr. William Edward Souter BCom
    IPAA, LLB (Adel), Chief Financial Officer
  • Mr. Michael Roberts
    Head of Investor Relations & Corporate Communications
  • Dr. Fujun Li Ph.D.
    Head of Manufacturing
  • Mr. Peter Gordon Webse B.Bus (Age 61)
    FCIS, FCPA, FGIA, M.A.I.C.D., Company Secretary

Key Competitors

View All Competitors

Insiders


ACW Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Actinogen Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Actinogen Medical investors own include Dynavax Technologies (DVAX), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin (CEY), Countryside Partnerships (CSP), Enbridge (ENB), EQTEC (EQT) and Exact Sciences (EXAS).

This page (ASX:ACW) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners
[Urgent!] Generational Wealth Gameplan
Crypto 101 Media
Biden’s $374B Giveaway Into This Sector
DTI
Biden replacement revealed?
Paradigm Press
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
The Next Nvidia?
InvestorPlace
How Biden has already won 2024
Porter & Company
Options trading has suddenly become more reliable.
Eagle Publishing
1970’s computer coder issues shocking A.I. warning
TradeSmith